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Abstract
Background Older adults are especially susceptible to
adverse consequences of potentially inappropriate medi-
cations (PIMs), such as benzodiazepine receptor agonists
(BZDRAs), due to age-related pharmacokinetic and phar-
macodynamic changes. Although some risk factors for
BZDRA use in older adults have been identified, the role of
rural versus urban residence is less clear.
Objective To describe BZDRA use in rural versus urban
older adults using pharmaceutical claims from Pennsylva-
nia’s Pharmaceutical Assistance Contract for the Elderly
(PACE) program.
Methods The sample consisted of older adults enrolled in
Pennsylvania’s Healthy Steps for Older Adults and partic-
ipated in Pennsylvania’s PACE program. Independent
sample t tests and contingency tables were used to examine
residence differences. Multivariate binary logistic model-
ing was performed.
Results The total sample (N = 426) was 305 (71.6 %) urban-
dwelling adults and 121 (28.4 %) rural-dwelling adults.
Rural participants were more likely to be male, white,
married, and have less than a high school education com-
pared with urban participants (p\.01). Specifically, 25 % of
rural-dwelling adults received a BZDRA compared with 15
% of urban-dwelling adults (p = 0.02). Three variables
reached statistical significance for predicting BZDRA use in
a multivariate model: rural residence (OR 2.58, 95 % CI
1.39–4.79), history of anxiety/depression (OR 4.20, 95 % CI
2.39–7.46), and number of medications (OR 1.11, 95 % CI
1.02–1.21).
Conclusions BZDRA prescription differences in older,
rural-dwelling adults further highlights the need for geri-
atric and mental health specialists to provide specialized
care to this population. Rural healthcare professionals may
be less aware of PIMs for older adults, and initiatives to
support geriatric services and provide education for exist-
ing providers may be beneficial.
Key Points
25 % of older, rural-dwelling adults received a
benzodiazepine receptor agonist compared with 15 %
of urban-dwelling older adults based on
Pennsylvania’s Pharmaceutical Assistance Contract
for the Elderly program claims data (p = 0.02).
Rural residence, history of anxiety/depression, and
total medication count predicted use of
benzodiazepine receptor agonists.
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1 Introduction
Potentially inappropriate medications (PIMs) are those
medications where risks associated with their use outweigh
possible benefits [1]. Due to pharmacokinetic and phar-
macodynamic changes associated with aging, older adults
are especially susceptible to the adverse consequences of
PIMs [2]. The repercussions of this increased sensitivity
may be readily seen with benzodiazepine receptor agonists
(BZDRAs), which include both traditional benzodiazepines
and the non-benzodiazepine receptor agonist sleep aids of
zolpidem, eszopiclone, and zaleplon (commonly known as
‘‘Z’’ drugs’’). BZDRAs have been associated with serious
adverse events in the elderly, including cognitive impair-
ment, delirium, falls, fractures, and motor vehicle crashes
[3, 4].
Despite mounting information regarding these adverse
consequences, use of BZDRAs in older adults has
remained constant over the previous decade [7]. Recent
studies estimate that between 12 and 32 % of older adults
receive a benzodiazepine, with rates exceeding 50 % in
those older adults with depression or anxiety [8]. More-
over, older adults are more likely to receive benzodi-
azepines for longer periods (i.e., C120 days) than their
younger counterparts [9]. Similarly, a nationally represen-
tative survey found that approximately one-third of all
prescriptions for non-benzodiazepine BZDRA sleep aids
from 1993–2010 were for adults C65 years old [10]. Sleep
aids, particularly ‘‘Z’’ drugs, are considered inappropriate
in older adults, specifically because of possible drug-dis-
ease interactions in the elderly. BZDRAs, including the
‘‘Z’’ drugs, have been associated with cognitive impair-
ment, and there is recent evidence that suggests a possible
link with dementia, although this relationship needs to be
further delineated [5, 6].
Although some risk factors for inappropriate BZDRA
use in older adults have been identified, the role of rural
versus urban residence is less clear. Recently, Edelstein
et al. [11] reported that older adults residing in rural
Pennsylvania were 1.5 times as likely (p = 0.045) to use
anxiolytics (e.g., benzodiazepines) and nearly twice as
likely (p = 0.33) to use sedative-hypnotics (i.e., non-ben-
zodiazepine receptor agonist sleep aids) than their urban
counterparts. However, medication use data in this study
were derived from participant self-report, which may
increase the likelihood of exposure misclassification com-
pared with more objective measures of medication uti-
lization. Therefore, the purpose of this study was to
describe BZDRA use in rural versus urban older adults
using pharmaceutical claims data from Pennsylvania’s
Pharmaceutical Assistance Contract for the Elderly
(PACE) program. It was hypothesized that older, rural-
dwelling adults would be more likely to use BZDRAs
compared to their urban counterparts.
2 Methods
2.1 Study Design
This correlational study was a secondary analysis of data
collected for Falls-Free PA, a research study comparing
falls incidence among older adults completing Pennsyl-
vania’s Healthy Steps for Older Adults (n = 814) and a
comparison group of older adults who did not complete
the program but attended the same senior centers offering
Healthy Steps (n = 1015). Details of the design and out-
comes of Falls Free PA have been reported previously
[12]. After providing informed consent, participants
completed baseline interviews and received monthly fol-
low-up phone calls for a year. The University of Pitts-
burgh Institutional Review Board approved the parent
study.
2.2 Sample
The sample for this secondary analysis was older adults
enrolled in Pennsylvania’s Healthy Steps for Older Adults
program between 2010 and 2011 who also participated in
Pennsylvania’s PACE program during that time (N = 426).
Falls-Free PA enrolled subjects from 19 counties from
Healthy Steps senior center sites between 2010 and 2011.
All subjects completed baseline interviews after providing
informed consent and received monthly follow-up phone
calls for up to a year. Inclusion criteria were: 50 years of
age or older and attending PA Department of Aging pro-
grams at Healthy Step sites. Exclusion criteria were
inability to provide informed consent, language spoken
other than English or Spanish, and inability to participate in
telephone follow-up calls. Additional information and
details regarding recruitment and follow-up are available
[11, 13]. Eligibility criteria for PACE include: 65 years of
age or older; Pennsylvania residence for at least 90 days
prior to date of application; not being currently enrolled in
Department of Public Welfare’s Medicaid prescription
benefits; and last calendar year’s income for a single person
being BUS$14,500 or, for a married couple, a combined
income BUS$17,700. The PACE Annual Report for 2011
showed 134,255 Pennsylvanians were enrolled in PACE
from 2010 to 2011 [14, 15].
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2.3 Measures
2.3.1 Descriptive Variables
Sociodemographic variables included age (in completed
years) as a continuous variable and gender (male/female),
race (white/non-white), marital status (married/ not mar-
ried), living situation (living with someone/not living with
someone), and education (less than high school [HS]/any
HS/ beyond HS) as categorical variables. Medical condi-
tions were coded as binary variables (yes/no) in response to
the question, ‘‘Has a doctor ever told you that you had
(a)…’’ and included 17 medical conditions. The total
number of prescription medications (up to 15 medications)
was self-reported at baseline [12].
2.3.2 Urban Rural Classification
Rural-Urban Continuum Codes from the US Department of
Agriculture system were used to determine urban and rural
residence based on county of residence [16]. Similar to the
original paper by Edelstein et al. [11], we used population
size to create a dichotomous location variable: urban
(counties with C250,000 residents) or rural (counties with
\250,000 residents).
2.3.3 Exposure Classification
Given their similar mechanisms of action and adverse risk
profiles, benzodiazepines and non-benzodiazepine receptor
sleep aids were grouped into one exposure category [3].
Relevant medications were identified by a clinical geriatric
pharmacist (JN) according to explicit criteria [3]: alpra-
zolam, chlordiazepoxide, clonazepam, clorazepate, diaze-
pam, estazolam, eszopiclone, flurazepam, lorazepam,
oxazepam, quazepam, temazepam, triazolam, zaleplon, and
zolpidem. Any BZDRA use was categorized as ‘‘yes’’ if the
participant received at least one BZDRA per PACE claims
data during enrollment in the study. PACE maintains a
prospective drug utilization review to ensure ‘‘safe and
effective use of medications,’’ including reviewing safety
issues related to the medications and communicating with
patient’s physicians [17].
2.3.4 Predictors of Benzodiazepine Receptor Agonist
(BZDRA) Use
Predictors were chosen a priori based on a comprehensive
review of the literature to identify potential confounders
that may influence benzodiazepine use, including
sociodemographic characteristics (i.e., age, education,
gender, race, and marital status), history of anxiety/de-
pression, and total number of medications [18–21].
2.4 Analysis
Statistical analyses were conducted using IBM SPSS
Statistics v.23 (IBM Corporation, Armonk, NY, USA).
Exploratory analyses were first employed for the screening
for any data anomalies, including outliers and missing data.
Missing data were analyzed by both amount and pattern.
Only seven participants (1.6 %) had missing data on one
variable used in analysis. We also examined for patterns of
missing data and found that data were missing completely
at random (MCAR) using Little’s MCAR test [v2(7) = 9.74,
p = 0.20]. No imputation was performed, as they appeared
to be a random subset of the study sample. Thus, the seven
participants with missing data were omitted in the final
analysis. Descriptive statistics were calculated as means
and standard deviations for continuous variables and fre-
quencies and percentages for categorical variables for the
total sample and by rural/urban residence for all sociode-
mographic variables, medical conditions (individual and
total), total number of medications, and BZDRA use.
Differences between types of residence were assessed
using independent sample t tests for continuous variables
and contingency tables with chi-square tests of indepen-
dence (or Fisher’s Exact tests if cells were sparsely popu-
lated) for categorical variables. Binary logistic regression
modeling was performed to examine a priori predictors of
benzodiazepine receptor agonist use, as well as possible
interactions between predictor variables for these out-
comes. Adjusted odds ratios (ORs) with 95 % confidence
intervals (CIs) were estimated from full multivariate binary
logistic regression models, where identified covariates
were adjusted for, and ultimately contained all predictors
of interest. A stepwise approach was also used to confirm
findings. Level of statistical significance was set at\0.05
for two-sided hypothesis testing.
3 Results
The total sample (N = 426) was comprised of 305 (71.6 %)
urban-dwelling older adults and 121 (28.4 %) rural-
dwelling older adults. As seen in Table 1, rural participants
were more likely to be male, white, married, and less likely
to have more than a high school education when compared
to their urban counterparts (p\ 0.01). On average, rural-
dwelling older adults also reported taking more total
medications at baseline than urban-dwelling older adults
(4.95 ± 3.31 medications vs. 4.21 ± 3.04 medications,
respectively, p = 0.03). Specifically, 25 % of rural-dwelling
older adults received a BZDRA, compared to 15 % of
urban-dwelling older adults (p = 0.02). There were no
differences between rural and urban participants with
regard to age, living situation, medical conditions, self-
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reported anxiety/depression, or total number of self-re-
ported medical conditions.
Using multivariate binary logistic regression consider-
ing all predictor variables, the full model demonstrated a
good fit [vH-L
2 (8) = 4.70, p = 0.79] and three predictors were
identified as significantly independently associated with
BZDRA use: rural residence (OR 2.58, 95 % CI
1.39–4.79), history of anxiety/depression (OR 4.22, 95 %
CI 2.39–7.46, and total number of medications (OR 1.11,
95 % CI 1.02–1.21) (Table 2). These results suggest that
rural residents had 2.58 times the odds of BZDRA use
compared to urban residents; and those participants with a
history of anxiety or depression had 4.20 times the odds of
BZDRA use compared to participants without a history of
anxiety or depression. For each additional medication used,
the odds of using a BZDRA increased by 11 %. Based on
forward stepwise regression, the same three predictor
variables were retained in the parsimonious model for
BZDRA use. Odds ratios, confidence limits, and signifi-
cance values were similar in both models.
Table 1 Baseline characteristics of Falls-Free Pennsylvania’s Pharmaceutical Assistance Contract for the Elderly (PACE) participants (N = 426)
Characteristic Total sample Residence p value
Rural (n = 121) Urban (n = 305)
Sociodemographics
Age (years), mean ± standard deviation (SD) 79.16 ± 6.72 79.81 ± 6.41 78.90 ± 6.83 0.21
Female, n (%) 378 (88.7) 95 (78.5) 283 (92.8) \0.01
Whitea, n (%) 388 (91.3) 119 (98.3) 269 (88.2) \0.01
Marriedb, n (%) 44 (10.3) 23 (19.0) 21(6.9) \0.01
Lives with someoneb, n (%) 108 (25.5) 33 (27.3) 75 (24.8) 0.59
Education, n (%) \0.01
Less than high school 86 (20.2) 30 (24.8) 56 (18.4)
Any high school 244 (57.3) 78 (64.5) 166 (54.4)
Beyond high school 96 (22.5) 13 (10.7) 83 (27.2)
Medical conditionsc
Anxiety or depression, n (%) 98 (23.1) 30 (22.4) 68 (25.0) 0.56
Arthritis, n (%) 299 (70.7) 84 (70.6) 215 (70.7) 0.98
Cancer, n (%) 84 (19.8) 29 (24.2) 55 (18.1) 0.16
Cognitive impairment/ problems with memory, n (%) 20 (4.7) 4 (3.3) 16 (5.3) 0.39
Congestive heart failure, n (%) 36 (8.6) 12 (10.2) 24 (8.0) 0.48
COPD or asthma, n (%) 61 (14.4) 16 (13.3) 45 (14.8) 0.70
Diabetes, n (%) 122 (28.8) 42 (35.0) 80 (26.4) 0.08
Fracture after age 50 years, n (%) 117 (27.7) 25 (21.0) 92 (30.3) 0.06
Glaucoma, n (%) 46 (10.9) 14 (11.7) 32 (10.6) 0.74
Heart attack, n (%) 43 (10.2) 17 (14.3) 26 (8.6) 0.08
High blood pressure, n (%) 321 (75.9) 97 (80.8) 224 (73.9) 0.13
Inner ear problem, n (%) 68 (16.2) 22 (18.8) 46 (15.2) 0.37
Macular degeneration, n (%) 59 (14.0) 17 (14.3) 42 (13.9) 0.92
Numbness in feet/ peripheral neuropathy, n (%) 81 (19.2) 29 (24.4) 52 (17.2) 0.09
Osteoporosis, n (%) 127 (30.5) 35 (29.9) 92 (30.8) 0.87
Parkinson disease, n (%) 3 (0.7) 1 (0.8) 2 (0.7) 1.00d
Stroke, n (%) 56 (13.2) 17 (14.2) 39 (12.8) 0.71
Total number of medications, mean ± SD 4.42 ± 3.13 4.95 ± 3.31 4.21 ± 3.04 0.03
Benzodiazepine receptor agonist use, n (%) 77 (18.1) 30 (24.8) 47 (15.4) 0.02
COPD chronic obstructive pulmonary disease
a n = 425
b n = 424
c All medical conditions are in response to the question, ‘‘Has a doctor ever told you that you had (a)…’’
d Fisher’s Exact test was used due to cells with expected counts less than 5
Italicised p-values indicate statistical significance (p\ 0.05)
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4 Discussion
This study is among the first to examine the association of
rural versus urban residence and benzodiazepine use in a
population of older adults. Overall, this study found that
prevalence of BZDRA use was higher in rural-dwelling,
older Pennsylvania adults compared with their urban
counterparts, at 25 and 15 %, respectively. Previously,
Edelstein et al. [11] evaluated the rate of anxiolytic and
sedative-hypnotic use among participants included in
Healthy Steps for Older Adults using medication self-report
and found that 8 % of rural dwelling older adults and 5 %
of urban-dwelling older adults used BZDRAs. The present
study combined data for participants enrolled in both
Healthy Steps for Older Adults and the Pennsylvania
Pharmaceutical Contract for Assistance for the Elderly
(PACE) program. Rates of BZDRA use captured using
PACE claims data were higher than those detected using
self-report; however, the magnitude of the difference was
similar.
These findings are consistent with previous studies that
suggest that rural residents may be at increased risk for
inappropriate prescribing [22–24]. Specifically, Lund et al.
[24] found that rural Veterans in the South and Northeast
(including Pennsylvania) were more likely to receive
inappropriate medications, which included certain
BZDRAs. Rural residence has previously been associated
with challenges accessing health services [25]. However,
the rates of use of BZDRAs detected in the current study
reflect ready access to inappropriate medications. As such,
it is possible that the frequency of use is a reflection of
decreased access to high-quality, geriatric-focused care
services, including non-pharmacologic interventions such
as psychotherapy [24, 26].
In addition to urban versus rural residence, it is not
surprising that participants with a history of depression or
anxiety were four times as likely to receive a BZDRA as
these medications are frequently used to treat psychiatric
and sleep disorders. Indeed, this is nearly identical to the
fivefold increased risk identified in another recent study
evaluating benzodiazepine use among older adults in the
community [7]. Selective serotonin reuptake inhibitors
(SSRIs) and serotonin-norepinephrine uptake inhibitors
(SNRIs) are considered a more appropriate treatment for
people with a history of anxiety and/or depression. We
found that in our study sample, only 11.3 % if the total
sample reported SSRI use (9.5 % urban and 15.7 % rural)
and 2.1 % reported SNRI use (2.3 % urban and 1.7 %
rural). Although anxiety and depression are primary indi-
cators for SSRI or SNRI use, there was fairly low reported
Table 2 Multivariate binary
logistic regression analysis of
predictors of benzodiazepine
receptor agonist use (N = 419)
Predictor Adjusted odds ratio (95 % confidence interval)
Age (years) 1.026 (0.982–1.073)
Residence
Urban (n = 301) 1.000
Rural (n = 118) 2.579 (1.387–4.794)**
Education
Less than high school
(n = 83)
1.000
Any high school (n = 241) 1.135 (0.543–2.372)
Beyond high school (n = 95) 1.645 (0.679–3.985)
Gender
Male (n = 47) 1.000
Female (n = 372) 1.707 (0.661–4.407)
Race
White (n = 382) 1.000
Black (n = 37) 0.351 (0.076–1.614)
Marital status
Married (n = 43) 1.000
Not married (n = 376) 0.973 (0.376–2.523)
Anxiety or depression
No (n = 286) 1.000
Yes (n = 133) 4.219 (2.386–7.459)***
Total number of medications 1.111 (1.021–1.208)*
* p\ 0.05, ** p\ 0.005; *** p\ 0.001
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use of these medications when compared to the BZDRA
use observed (15–25 %). The lower prevalence of these
indicated antidepressants and higher BZDRA prevalence
further points to inappropriate prescribing in this
population.
It is also important to note that, to date, benzodiazepines
have not been shown effective in treating depression.
Although benzodiazepines are effective in treating anxiety,
they are generally not preferred due to adverse drug profile
and addiction potential as well as availability of equally
efficacious and safer alternatives. It is noteworthy that we
did not find differences between rural and urban partici-
pants with a history of depression or anxiety that may help
explain the differences seen in BZDRA use. This may be a
combination of rural areas having fewer healthcare provi-
ders, limited health services, and possibly missed or
incorrect diagnoses by rural providers [27, 28].
Polypharmacy has also been consistently identified as a
predictor of inappropriate medication prescribing [20]. In
our study, the odds of BZDRA use increased by 11 % for
each additional medication received. Applying this finding
to an older adult receiving four medications, as per a recent
study [29], this represents a 48 % cumulative increased
odds of BZDRA use compared with an individual taking no
medications. We did not find any of the sociodemographic
variables to be significant predictors of BZDRA use, and
this may be due to small sample sizes for certain groups
within variables (e.g., male/ gender and black/ race).
The rates of BZDRA use among community-dwelling
older adults identified in this study are consistent with
recent literature. For example, in one study using data
from the National Ambulatory Medical Care Survey, 12 %
of older adults visiting ambulatory care clinics received a
benzodiazepine [7]. Moreover, these rates seem to be
rising, especially among the oldest old (i.e., C85 years
old) [7]. Importantly, between 30 and 50 % of older adults
use benzodiazepines chronically [9, 18]. Given the serious
repercussions of BZDRA on cognition (e.g., delirium) and
mobility (e.g., falls, fractures) in the elderly, the high rates
of BZDRA use detected in this study—especially among
rural dwellers—represents a target for quality improve-
ment interventions [3]. It is important to note that although
PACE maintains a prospective drug utilization review to
evaluate possible medication safety issues, this review
does not serve as a comprehensive review of all patients’
medical conditions and indications for medication use
[17]. Advantages of having both a single primary-care
provider and pharmacy reviewing all current medication
types, uses, dosages, and frequencies is ideal for providing
streamlined medication review and ensuring safety for the
patient. In a recent Cochrane Review examining psy-
chosocial interventions for BZDRA use, abuse, or inde-
pendence [30], cognitive behavioral therapy (CBT) plus
BZDRA taper more effectively reduced BZDRA use
compared to taper alone over 3 months. Although this
intervention for short-term BZDRA use reduction is
encouraging, reduced use was not sustained at 6 months.
Thus, CBT plus taper should be encouraged in both urban
and rural older adults; however, there should be an
emphasis on seeking specialty geriatric and psychiatric
providers to help maintain a BZDRA-free medication
regimen in this population.
Some strengths of the current study were BZDRA pre-
scription measurement, large sample size, older sample,
and collaboration with PACE. Prescription medication use
by participants was not self-report, which may have pro-
vided more accurate reports, especially in this older sample
taking multiple medications. Additionally, 21.3 % of
Pennsylvania’s population lives in rural areas, and this
secondary analysis was able to retain a fairly high number
of rural participants for inclusion (14.1 % of the entire
sample). Based on the current literature, this study is the
first of its kind to use data from participants in the PACE
program to explore benzodiazepine receptor agonist pre-
scriptions with an emphasis on differences between rural
and urban settings.
As with any observational study, some limitations
should be noted. This was a descriptive study, and conse-
quently there was no determination whether this discrep-
ancy between rural and urban residence resulted in
meaningful differences in adverse events. Additionally,
frequency and duration of use were not available. There-
fore, the authors were unable to calculate dose and
cumulative exposure, which may be more important when
considering health outcomes such as hip fracture. Another
limitation is that non-pharmacologic interventions, such as
psychotherapy, where not collected from participants at
baseline and, therefore, were not considered in analysis. It
may be that non-pharmacologic interventions to treat
conditions BZDRAs are being prescribed for are less
available in rural areas compared to urban areas. Addi-
tionally, it would have been ideal to have additional data
about diagnosis or history of insomnia for participants as
this may have provided further explanation for BZDRA use
and/or the relationship with depression.
Generalizability for the study may also be limited, as
only Pennsylvanians in lower socioeconomic classes were
captured when Falls Free PA and PACE databases were
combined. However, the rates identified in the current
study are similar to a previously-published study of ben-
zodiazepine use in older adults receiving governmental
prescription assistance, with 25 % of older adults receiving
benzodiazepines [31]. Moreover, though the sample was
predominately White, female, and married, there were
statistically significant differences noted between rural and
urban groups.
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5 Conclusion
This study confirms that rural residence may be an
important risk factor for BZDRA use. As with any medi-
cation, healthcare providers must weigh the benefits and
possible side effects of a medication prior to prescribing,
and the decision to prescribe BZDRAs in older, rural-
dwelling adults further highlights the need for geriatric and
mental health specialists to provide specialized care to this
population. Because healthcare professionals in rural set-
tings may be less aware of PIMs for older adults, initiatives
to support geriatric services, provide education for existing
providers, and improve prescribing in this setting may yield
beneficial results for older adults.
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